TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1567690

Group type: EXPERIMENTAL
Intervention: Dexamethasone, lorazepam, and prochlorperazine (DLP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lorazepam and prochlorperazine with placebo (LP)
Number of subjects: 84
Study: 31551517

Group type: EXPERIMENTAL
Intervention: Bortezomib (Bz) as part of the conditioning regimen and GvHD prophylaxis
Number of subjects: 25
Study: 30565422

Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) intervention during UDE
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard UDE without AV intervention
Number of subjects: 218
Study: 28347938

Group type: EXPERIMENTAL
Intervention: Influenza vaccination questionnaire (with or without sticky note)
Number of subjects: 13803

Group type: EXPERIMENTAL
Intervention: Sticky note requesting completion of the questionnaire
Number of subjects: 13803

Group type: EXPERIMENTAL
Intervention: Different cognitive targets (anticipated regret or beneficence) in questionnaires
Number of subjects: 13803

Group type: COMPARATOR
Intervention: Control 1 (no questionnaire)
Number of subjects: 13803

Group type: COMPARATOR
Intervention: Control 2 (demographics questionnaire)
Number of subjects: 13803
Study: 25557693

Group type: EXPERIMENTAL
Intervention: Test meal (240 mL, 12 kcal broth)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control meal (water)
Number of subjects: 42
Study: 24291952

Group type: EXPERIMENTAL
Intervention: Repetitive facilitative exercise (RFE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 0
Study: 21936759

Group type: EXPERIMENTAL
Intervention: Participants who watched clips of the individual with TBI engaged in conversation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Participants who listened to clips of the individual with TBI engaged in conversation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Participants who viewed the individual's movements as inappropriate
Number of subjects: 34
Study: 19158587

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 to 1 cm H2O)
Number of subjects: 12
Study: 17473091

Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours, starting within 6 hours after birth (rectal temperature maintained at 34.5 +/- 0.5 degrees C)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 218
Study: 15196399

Group type: EXPERIMENTAL
Intervention: Cuspid occlusal upheaving splint
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 20
Study: 12529076

Group type: EXPERIMENTAL
Intervention: Web-based survey mode, n = 3,500
Number of subjects: 7000

Group type: COMPARATOR
Intervention: U.S. mail-based survey mode, n = 3,500
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Web-based survey mode
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Web-based survey mode and U.S. mail-based survey mode
Number of subjects: 7000
Study: 9462604

Group type: EXPERIMENTAL
Intervention: Low-risk admissions for heart failure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-risk admissions for heart failure
Number of subjects: 120
Study: 8127120

Group type: EXPERIMENTAL
Intervention: Flash cefuroxime (1.5 gm intravenously at anesthetic induction and again 2 hours later)
Number of subjects: 203

Group type: COMPARATOR
Intervention: 48-hour cefuroxime (1.5 gm intravenously at anesthetic induction and again 2 hours later, then every 6 hours for 48 hours)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Flash cefuroxime
Number of subjects: 203

Group type: COMPARATOR
Intervention: 48-hour cefuroxime
Number of subjects: 203
Study: 2642873

Group type: EXPERIMENTAL
Intervention: Waiting time longer than 30 minutes after cleansing enema
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting time of 30 minutes or less after cleansing enema
Number of subjects: 0
Study: 1091397

Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 3
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.5‐mg doses of digoxin from lot 4
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.5‐mg doses of digoxin from one lot taken twice
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intersubject variation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urinary digoxin determinations
Number of subjects: 6
Study: 31378395

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (500 mg twice a day, adjustable to a maximum of four tablets and a minimum of one tablet a day)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo (two oral tablets a day)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 28514344

Group type: EXPERIMENTAL
Intervention: Erbium laser treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional surgical treatment (Control)
Number of subjects: 46
Study: 26101461

Group type: EXPERIMENTAL
Intervention: Red wine naturally enriched with resveratrol (NPVRW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: McDonald's meal (McDM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: McDonald's meal (McDM) + NPVRW
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPVRW
Number of subjects: 0
Study: 24711627

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study: 21849549

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over human visual cortex to induce illusory perceptions (phosphenes) at perceptual threshold.
Number of subjects: 0
Study: 20329608

Group type: EXPERIMENTAL
Intervention: Transcutaneous electro-acupuncture (TCEA) applied for 20 min before induction and throughout the operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anesthesia without TCEA (Control group)
Number of subjects: 60
Study: 17723882

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels less than 3.0 pg/mL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels between 3.0-5.3 pg/mL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels greater than or equal to 5.3 pg/mL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels less than 5.5 pg/mL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels between 5.5-9.0 pg/mL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum IL-15 levels greater than or equal to 9.0 pg/mL
Number of subjects: 54
Study: 15226326

Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin followed by docetaxel (A‐‐>T)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Concomitant doxorubicin and docetaxel (AT)
Number of subjects: 144
Study: 11804377

Group type: EXPERIMENTAL
Intervention: Psychometric questionnaires for quality of life assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal studies measuring quality of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised clinical trials for quality of life assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simpler instruments and specific training by research nurses
Number of subjects: 0
Study: 9562310

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in ALS patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in MS and HAM patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in patients with and without oligoclonal bands
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cerebrospinal fluid interleukin 6 (IL-6) levels in relation to clinical disease activity in MS
Number of subjects: 105
Study: 7832682

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (GaAlAs laser)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 3276193

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with 300 mg doxycycline
Number of subjects: 999

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 999
Study: 30055163

Group type: EXPERIMENTAL
Intervention: Electromechanical exoskeleton-assisted gait training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physical therapist-assisted gait training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study: 28402245

Group type: EXPERIMENTAL
Intervention: Levothyroxine (starting dose of 50 μg daily, or 25 μg if body weight <50 kg or with coronary heart disease)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 737
Study: 25577731

Group type: EXPERIMENTAL
Intervention: Real images exposure (n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hyper-real images exposure (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wait-list control group (n = 9)
Number of subjects: 28
Study: 23516012

Group type: EXPERIMENTAL
Intervention: Hydration ad libitum
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hydration
Number of subjects: 0
Study: 21909121

Group type: EXPERIMENTAL
Intervention: nsEERPE
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: nsEERPE with BNS
Number of subjects: 180

Group type: COMPARATOR
Intervention: EERPE
Number of subjects: 180

Group type: COMPARATOR
Intervention: EERPE with BNS
Number of subjects: 180
Study: 19750573

Group type: EXPERIMENTAL
Intervention: Small sphincterotomy combined with endoscopic papillary large balloon dilation (SES + ELBD)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 55
Study: 17540804

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Cotesting with cytology and HPV testing
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Hybrid Capture 2
Number of subjects: 1559
Study: 16563245

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 57
Study: 11872052

Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-mesh repair
Number of subjects: 300
Study: 10201430

Group type: EXPERIMENTAL
Intervention: Oculomicrotremor readings from parkinsonian patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oculomicrotremor readings from normal healthy volunteers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Medication withdrawn in one patient
Number of subjects: 22
Study: 7574280

Group type: EXPERIMENTAL
Intervention: Postoperative wrist splinting for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bulky dressing only
Number of subjects: 40
Study: 2406296

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine toothpaste
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2% triclosan toothpaste
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: water brushing
Number of subjects: 10
Study: 7356889

Group type: EXPERIMENTAL
Intervention: Chronic beta‐adrenoceptor blockade with oxprenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31602531

Group type: EXPERIMENTAL
Intervention: Surgical resection (SR)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Proton beam therapy (PBT)
Number of subjects: 345
Study: 31535099

Group type: EXPERIMENTAL
Intervention: Autogenous bone block grafts fixed at a distance (BBG‐D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resorbable poly‐D‐L‐lactide foil fixed at a distance (SonicWeld Rx shell technique [SWST])
Number of subjects: 30
Study: 28682955

Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 500
Study: 25032942

Group type: EXPERIMENTAL
Intervention: Microcirculation resuscitation group (nitroglycerin, enoximone, dopamine, dexamethasone)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard resuscitation group (fluids, noradrenaline, dobutamine, hydrocortisone)
Number of subjects: 90
Study: 23238293

Group type: EXPERIMENTAL
Intervention: Low-PA/high-OA (HOA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-PA diet
Number of subjects: 0
Study: 21814174

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 267

Group type: COMPARATOR
Intervention: Conventional PD solutions
Number of subjects: 267
Study: 19198801

Group type: EXPERIMENTAL
Intervention: Brace treatment (Dresden scoliosis orthosis)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Noncompliant group (no brace treatment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Compliant group (brace treatment)
Number of subjects: 90
Study: 16937304

Group type: EXPERIMENTAL
Intervention: Combination therapy (estramustine phosphate + endocrine therapy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Endocrine monotherapy
Number of subjects: 57
Study: 15665929

Group type: EXPERIMENTAL
Intervention: Beta-adrenoblockers and angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study: 11221552

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9164179

Group type: EXPERIMENTAL
Intervention: Filgrastim 5 micrograms/kg/d SC bolus injection
Number of subjects: 86

Group type: COMPARATOR
Intervention: Filgrastim 10 micrograms/kg/d SC continuous infusion
Number of subjects: 86
Study: 7693314

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (topical glucocorticoid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3297278

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with BCNU, cyclophosphamide, vincristine, and prednisone (BCVP) given every 6 weeks for an additional 18 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 111
Study: 31020442

Group type: EXPERIMENTAL
Intervention: Infographic
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Vignette
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mandated legislation
Number of subjects: 112
Study: 30066796

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Valproate (VPA) + Lamotrigine (LTG) polytherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Valproate (VPA) + Levetiracetam (LEV) polytherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 48
Study: 27218676

Group type: EXPERIMENTAL
Intervention: GS-5745 (multiple doses: 0.3, 1.0, 2.5 or 5.0 mg/kg IV every 2 weeks or 150 mg SC weekly)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: GS-5745 (multiple doses)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: GS-5745
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nonresponders to GS-5745
Number of subjects: 74
Study: 24725326

Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lid-margin hygiene (combined lid warming and massage)
Number of subjects: 31
Study: 23584092

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with left ventricular reconstruction
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1232
Study: 22195358

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day for 3 weeks, then 10 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Metoprolol (100 mg/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 79
Study: 19758285

Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - informed treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - informed possible active drug or placebo
Number of subjects: 123

Group type: COMPARATOR
Intervention: Group 3 (G3) - aware of placebo
Number of subjects: 123
Study: 16798186

Group type: EXPERIMENTAL
Intervention: Cell-saving device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard closed venous reservoir)
Number of subjects: 40
Study: 12735550

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 232

Group type: COMPARATOR
Intervention: Nonsurgical control
Number of subjects: 232
Study: 11122836

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study: 9302064

Group type: EXPERIMENTAL
Intervention: In situ vein grafts
Number of subjects: 91

Group type: COMPARATOR
Intervention: Reversed vein grafts
Number of subjects: 91
Study: 8335580

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) - 60 min of cycling, 3 days/week, at 60% VO2max for 10 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (UT) - no exercise training
Number of subjects: 13
Study: 3278232

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg per week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29631553

Group type: EXPERIMENTAL
Intervention: 10-week oral estrogen replacement (combination of ethinyl estradiol 0.03 mg and dienogest 2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28608971

Group type: EXPERIMENTAL
Intervention: Intervention (Research participation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Placebo arm)
Number of subjects: 20
Study: 25654108

Group type: EXPERIMENTAL
Intervention: OND + APREP
Number of subjects: 98

Group type: COMPARATOR
Intervention: OND
Number of subjects: 98
Study: 23113757

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention
Number of subjects: 956

Group type: COMPARATOR
Intervention: Mere measurement condition
Number of subjects: 956
Study: 21966519

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2mA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2mA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study: 18343373

Group type: EXPERIMENTAL
Intervention: Recombinant LH 75 IU/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16873437

Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharides (0.8 g/100 ml)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (maltodextrine)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharides
Number of subjects: 259
Study: 12493644

Group type: EXPERIMENTAL
Intervention: Sighs added during ventilation in prone position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sighs added during ventilation in supine position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ventilation without sighs) in prone position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ventilation without sighs) in supine position
Number of subjects: 10
Study: 10786231

Group type: EXPERIMENTAL
Intervention: Victims of political persecution (PTSD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8755837

Group type: COMPARATOR
Intervention: Hemodialyzed patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hemodialyzed patients (on the day of dialysis and on the following day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-dialyzed and hemodialyzed uremic patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 48
Study: 1899550

Group type: EXPERIMENTAL
Intervention: MMC + UFT
Number of subjects: 86

Group type: COMPARATOR
Intervention: MMC only (group A)
Number of subjects: 86
Study: 6284720

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31789451

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29952672

Group type: EXPERIMENTAL
Intervention: Complex strength training
Number of subjects: 28
Study: 27487300

Group type: EXPERIMENTAL
Intervention: 10-week MBSR bibliotherapy intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 92
Study: 25554233

Group type: EXPERIMENTAL
Intervention: Enhanced REP
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Standard REP
Number of subjects: 1531
Study: 24292313

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Betamethasone (control)
Number of subjects: 44
Study: 20970963

Group type: EXPERIMENTAL
Intervention: 0.5% PVP-I solution (Arakeri's iodine solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 19920268

Group type: EXPERIMENTAL
Intervention: Computer-based decision-support system (10 centers, 753 patients)
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Paper guidelines (posters and pocket cards) (10 centers, 1015 patients)
Number of subjects: 2866
Study: 18219779

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 15789981

Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 80
Study: 14564895

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bright light exposure (> 3000 lux)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dim light exposure (< 10 lux)
Number of subjects: 16